πŸ‡ΊπŸ‡Έ FDA
Patent

US 10925961

Vaccines with CD40 ligand as an adjuvant

granted A61KA61K2039/53A61K2039/55516

Quick answer

US patent 10925961 (Vaccines with CD40 ligand as an adjuvant) held by Inovio Pharmaceuticals, Inc. expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inovio Pharmaceuticals, Inc.
Grant date
Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/53, A61K2039/55516, A61K2039/585, A61K39/0011